Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.

Matthew Pellan ChengJosé L OrejasEsther Arbona-HaddadTyler D BoldIsaac H SolomonKaiwen ChenAlisha PanditAmanda E KusztosKaelyn C CumminsAlexis LiakosFrancisco M MartySophia KooSarah P Hammond

Published in: Mycoses (2019)

In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
stem cells
bone marrow
patient reported